Watch for full data presentation at ACR on November 11, 2026, which will provide detailed subgroup and safety data. The positive Phase 3 readout supports potential regulatory filings for efgartigimod in autoimmune myositis, expanding argenx's approved indications beyond gMG and CIDP.
Price Chart
Executive Summary
argenx announced positive Phase 3 ALKIVIA results for efgartigimod in autoimmune myositis (IMNM and DM), meeting the primary endpoint with a 15.4-point greater improvement in TIS vs placebo at Week 52 (p=0.0011). This is the first registrational study for an FcRn blocker in this indication, addressing a large unmet need with no approved treatments for IMNM. The data will be presented as a late-breaking oral at ACR Convergence 2026 on November 11.
Key Facts
- Phase 3 ALKIVIA study met primary endpoint: 15.4-point greater improvement in mean TIS vs placebo at Week 52 (47.95 vs 32.56; p=0.0011) in combined IMNM and DM population.
- Improvements observed as early as Week 4 and sustained through 52 weeks with steroid tapering.
- First registrational study of an FcRn blocker in autoimmune myositis; no approved treatments exist for IMNM.
- Late-breaking oral presentation at ACR Convergence 2026 on November 11, 2026.
- Efgartigimod was well-tolerated with safety profile consistent with prior studies.
- Approximately 100,000 people in the US live with autoimmune myositis, including ~20,000 with IMNM and ~40,000 with DM.
Financial Impact
Positive pipeline expansion into a new indication with large unmet need; no financial figures provided in filing.
Risk Factors
- Regulatory approval for autoimmune myositis is not guaranteed; FDA/EMA may require additional data.
- Competition from other FcRn blockers and emerging therapies in development for myositis.
- Commercial uptake depends on pricing, reimbursement, and differentiation from corticosteroids/immunosuppressants.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-116751 |
| Document: tm2627805d1_6k.htm | 0001104659-26-116751 |
| Document: 0001104659-26-116751-index-headers.html | 0001104659-26-116751 |
| Document: 0001104659-26-116751-index.html | 0001104659-26-116751 |
| Document: 0001104659-26-116751.txt | 0001104659-26-116751 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 6-K | $875.76 | awaiting T+20 | — | $882.48 (+0.77%) |
Oct 19, 2026 8d ago | 6-K | $825.61 | awaiting T+20 | — | $882.48 (+6.89%) |
Oct 8, 2026 19d ago | 6-K | $818.63 | awaiting T+20 | — | $882.48 (+7.80%) |
Sep 29, 2026 28d ago | 6-K | $970.66 $871.52 | ▼ −10.21% | ▼ −10.87% | $882.48 (−9.08%) |
Sep 10, 2026 6w ago | Institutional Cluster | $984.04 $818.63 | ▼ −16.81% | ▼ −18.93% | $882.48 (−10.32%) |
Aug 17, 2026 10w ago | 6-K | $987.84 $990.54 | ▲ +0.27% | ▲ +1.80% | $882.48 (−10.67%) |
Aug 6, 2026 11w ago | Press Release | $875.30 $1,053.46 | ▲ +20.35% | ▲ +19.75% | $882.48 (+0.82%) |
Jul 27, 2026 13w ago | 6-K | $888.82 $1,011.11 | ▲ +13.76% | ▲ +10.46% | $882.48 (−0.71%) |
Jul 27, 2026 13w ago | Press Release | $888.82 $1,011.11 | ▲ +13.76% | ▲ +10.46% | $882.48 (−0.71%) |
Jul 23, 2026 13w ago | Press Release | $924.60 $1,038.12 | ▲ +12.28% | ▲ +8.97% | $882.48 (−4.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers